Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease

By Ryu J.K.   Kim S.U.   McLarnon J.G.  

Experimental Neurology, Vol. 183, Iss. 2, 2003-10 ,pp. : 700-704

Elsevier

Access to resources Recommend Favorite

The IGF-I Amino-Terminal Tripeptide Glycine-Proline-Glutamate (GPE) Is Neuroprotective to Striatum in the Quinolinic Acid Lesion Animal Model of Huntington's Disease

By Alexi T.   Hughes P.E.   van Roon-Mom W.M.C.   Faull R.L.M.   Williams C.E.   Clark R.G.   Gluckman P.D.  

Experimental Neurology, Vol. 159, Iss. 1, 1999-09 ,pp. : 84-97

Elsevier

Access to resources Recommend Favorite

Maintenance of Susceptibility to Neurodegeneration Following Intrastriatal Injections of Quinolinic Acid in a New Transgenic Mouse Model of Huntington's Disease

By Petersen A.   Chase K.   Puschban Z.   DiFiglia M.   Brundin P.   Aronin N.  

Experimental Neurology, Vol. 175, Iss. 1, 2002-05 ,pp. : 297-300

Elsevier

Access to resources Recommend Favorite

Quinolinic Acid Released from Polymeric Brain Implants Causes Behavioral and Neuroanatomical Alterations in a Rodent Model of Huntington's Disease

By Haik K.L.   Shear D.A.   Schroeder U.   Sabel B.A.   Dunbar G.L.  

Experimental Neurology, Vol. 163, Iss. 2, 2000-06 ,pp. : 430-439

Elsevier

Access to resources Recommend Favorite

Neuroprotective Effects of the 2 -Adrenoceptor Antagonists, (+)-Efaroxan and (+/-)-Idazoxan, against Quinolinic Acid-Induced Lesions of the Rat Striatum

By Martel J.-C.   Chopin P.   Colpaert F.   Marien M.  

Experimental Neurology, Vol. 154, Iss. 2, 1998-12 ,pp. : 595-601

Elsevier

Access to resources Recommend Favorite